ClinicalTrials.gg
CompletedNCT02076620Updated Apr 4, 2022

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

A Phase 1 interventional study of L19TNFα and Doxorubicin in Advanced Solid Tumors Amenable to Anthracycline Therapy and Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy, sponsored by Philogen S.p.A.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-04.

Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jan 2013, registered Feb 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing doxorubicin in Sarcoma — 13 open to participants now, 14 under way, 2 of them phase 3. Doxorubicin · Sarcoma.

Enrollment
41st of 60
29 · median 42
Started
2013
with 1 other
Phase 1
15 of 65
3 open now
Registered
39th of 65
by date

Among the 65 studies testing doxorubicin in Sarcoma, this one is the 41st largest by enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2013, is one of 15 in phase 1, and was the 39th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

13 of the 65 studies testing doxorubicin in Sarcoma are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing doxorubicin in Sarcoma, or all of them as a file.
02

Study summary

Prospective, open-label, non randomized, dose escalation study that will be conducted in sequential cohorts of patients.

Read the detailed description

In the clinical trial 3-6 patients will be assigned to L19TNFalfa at one of the following sequential dose levels (10.4 µg/kg, 13 µg/kg and 17 µg/kg) in combination with a fixed dose of doxorubicin.

The RD will be defined following a traditional 3+3 design. The dose escalation will continue until the MTD is found, that is until at least two patients among a cohort of three to six patients experience a dose limiting toxicity (DLT).

03

Conditions studied

  • Advanced Solid Tumors Amenable to Anthracycline Therapy
  • Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy

Keywords

  • L19
  • monoclonal
  • antibody
  • doxorubicin
  • TNFα
  • solid tumour
  • sarcoma, breast cancer, lung carcinomas, gynecological cancer
  • anthracycline
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or cytologically confirmed advanced solid cancer deemed suitable for combination therapy of L19TNFα and doxorubicin.
  • Patients aged ≥18 years old with advanced or solid tumor in whom standard anticancer therapies have been exhausted and who are amenable for a doxorubicin monotherapy according to the discretion of the Principal Investigators and previously treated with a cumulative dose of anthracyclines (≤ 300 mg/m2).
  • (ECOG) performance status ≤ 2.
  • Patients may have received previous chemotherapy (>4 weeks prior therapy) or radiation therapy (>6 weeks prior therapy), but they must be amenable for doxorubicin treatment according to the discretion of the Principal Investigator.
  • Patients must have at least one unidimensionally by computed tomography as defined by criteria version 1.1. This lesion must not have been irradiated during previous treatments.
  • Previous anthracycline therapy, including liposomal doxorubicin, for metastatic and/or adjuvant disease is allowed. However, patients must not have received a cumulative anthracycline dose of more than 300 mg/m2 of doxorubicin, nor more than 500 mg/m2 of epirubicin, nor more than 600 mg/m2 of pegylated or non-pegylated liposomal doxorubicin prior to study entry, in order to avoid anthracycline-associated cardiotoxicity.
  • more than 3 months.
  • (ANC) ≥ 1.5 x 109/L, ≥ 100 x 109/L and (Hb) ≥ 9.5 g/dl.
  • All acute adverse effects (excluding alopecia) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have resolved to ≤ Grade 1, except elevated liver transaminases judged to be associated with tumor infiltration (see below) (graded according to the National Cancer Institute v.4.02 dated September 15, 2009).
  • Alkaline phosphatase (AP), (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x (ULN), and total ≤ 2.0 mg/dL, unless liver involvement by the tumor, in which case the transaminase levels up to 5 x ULN are allowed.
  • Creatinine ≤ 1.5 ULN or 24 h ≥ 60 mL/min.
  • Testing negative for acute or chronic infection with or C virus, or 1 or 2.
  • Negative pregnancy test for females of at the screening visit.
  • Commitment from patient to practice medically appropriate/acceptable method of beginning 30 days before study entry and continuing until 6 months following the last treatment with study drug. Excluding women without childbearing potential; menopause at least 2 years earlier, tubal ligation at least 1 year earlier, or total hysterectomy. The definition of effective contraception will be based on the guidelines ICH M3 rev2.
  • Evidence of a personally signed and dated EC-approved ICF indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the study.
  • Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

ICF must be obtained for all the patients before enrollment into the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breast-feeding. Patients must agree to use effective , or be surgically sterile or . The definition of effective contraception will be based on the guidelines ICH M3 rev2.
  • Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the subject at undue risk or interfere with the study.
  • Presence of known . If patient is symptomatic, negative CT scan within two months before study beginning is required. However, presence of controlled brain metastases (i.e., evaluated as SD of PR after radiotherapy) is allowed.
  • Known cancer of other primary origin within the prior 5 years.
  • History of chronic or C, or chronic active hepatitis or active diseases.
  • Cardiac disease as manifested by any of the following:

    • > Grade II heart failure, graded per (NYHA) criteria.
    • History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
    • Irreversible cardiac arrhythmias requiring permanent medication.
    • less than the institutional lower limit of normal as assessed by MUGA scan or echocardiogram.
  • Uncontrolled hypertension.
  • Ischemic peripheral vascular disease (Grade IIb-IV).
  • Severe rheumatoid arthritis.
  • Severe diabetic retinopathy.
  • History of allograft or stem cell transplantation.
  • Major surgery or trauma within 4 weeks prior to start of study treatment.
  • Known history of allergy to TNFα, Anthracyclines or other intravenously administered human proteins/peptides/antibodies.
  • Chemotherapy (standard or experimental), or therapy with an agent within 4 weeks prior to start of study treatment, and radiation within 6 weeks prior therapy.
  • Cumulative exposure to anthracycline-containing chemotherapy (patients received a cumulative anthracycline dose of more than 300 mg/m2 of doxorubicin or of more than 500 mg/m2 of epirubicin or pegylated or non-pegylated liposomal doxorubicin), prior to study entry precluding the application of at least an additional 150 mg/m2 doxorubicin (total dose for 2 cycles of study therapy).
  • Treatment with an investigational study drug within six weeks before beginning of treatment with L19TNFα.
  • Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment.
  • Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
  • Neuropathy > Grade 1.
  • Patient requires or is taking or other drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute reactions is not considered an exclusion criterion.
  • Concurrent therapy with anticoagulants at full dose .
  • Participation in another interventional clinical trial during participation in this trial.
  • Expectation that the patient will not be able to complete at least 6 weeks of therapy.
  • Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    L19TNFα + doxorubicin

    Only one arm is specified. Patients will be treated in three cohorts with 3 different dosages of L19TNFα in combination with 60 mg/m2 of doxorubicin, according to the following study design: cohort 1 --\> 10.4 μg/kg L19TNFα + doxorubicin; cohort 2 --\> 13 μg/kg L19TNFα + doxorubicin; cohort 3 --\> 17 μg/kg L19TNFα + doxorubicin.

    Drug: L19TNFα · Drug: Doxorubicin

Interventions

  • DrugL19TNFα

    L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.

  • Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    To assess the safety, including maximum tolerated dose (MTD), recommended dose (RD) and dose limiting toxicity (DLT) of L19TNFα in combination with doxorubicin, the following will be considered: * Adverse Events (AEs) assessment based on CTCAE v.4.03, including DLT assessment. * Standard laboratory (haematology, biochemistry and urinalysis) parameters. * Physical examination findings including assessment of vital signs and physical measurements (blood pressure, heart rate, body weight).

    Time frame: From day 1 to day 29

Secondary outcomes

  1. Pharmacokinetics assessment of L19TNFα

    Time frame: At day 1 of week 1

  2. Human anti-fusion protein antibodies (HAFA) levels

    Investigate the potential induction of human anti-fusion protein antibodies (HAFA) through standard laboratory analysis.

    Time frame: 1) at day 1, 2) at day 22, 3) at day 43, 4) at day 64, 5) at day 85, 6) at day 106, 7) from day 31 up to day 143, 8) from day 73 up to day 185

  3. Objective response rate (ORR)

    To investigate the antitumor activity

    Time frame: Up to 1 year

  4. Median progression free survival (mPFS)

    To investigate the antitumor activity

    Time frame: Up to 1 year

  5. Median overall survival (OS)

    To investigate the antitumor activity

    Time frame: Up to 1 year

07

Study locations

2 sites
  • Universitätsklinikum Münster
    Münster, Germany
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Jan 2018, 60 months.

Of 72 industry-sponsored phase 1 interventional studies under Sarcoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 66. This study's 60 months is above that.

Counting every sponsor, half of 161 studies reached it within 56 months; a quarter within 35 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2014
First posted
Mar 3, 2014
StartActual
Jan 16, 2013
Primary completionActual
Jan 25, 2018
CompletionActual
Jan 25, 2018
Last update
Apr 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02076620
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Mar 3, 2014
Start date
Jan 16, 2013
Primary completion
Jan 25, 2018
Completion
Jan 25, 2018
Last update
Apr 4, 2022

Study contacts

Filippo De Braud, Dr
principal investigator · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Christoph Schliemann, Dr
principal investigator · Universitätsklinikum Münster

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion